PHARMAC and cardiovascular health in New Zealand

New Zealand Medical Journal

Volumn 121, Issue 1270, 2008, Pages 102-105

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALENDRONIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; BETA INTERFERON; CLOPIDOGREL; ERYTHROPOIETIN; GABAPENTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMATINIB; LAMIVUDINE; SIMVASTATIN; VENLAFAXINE; CARDIOVASCULAR AGENT;

AUSTRALIA; CARDIOVASCULAR DISEASE; CLINICAL DECISION MAKING; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DYSLIPIDEMIA; HUMAN; LETTER; LOW DRUG DOSE; MORBIDITY; MORTALITY; NEUROPATHIC PAIN; NEW ZEALAND; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY PREVENTION; SECONDARY PREVENTION; DRUG APPROVAL; DRUG INDUSTRY; HEALTH STATUS; NOTE; ORGANIZATION AND MANAGEMENT;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG APPROVAL; DRUG INDUSTRY; HEALTH STATUS; HUMANS; NEW ZEALAND;

EID: 42149179440     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Letter

References (13)

1. Stewart RA, North FM, Sharples KJ, et al. Long-term Intervention with Pravastatin in Ischaemic Disease Study Investigators. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: Findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study. N Z Med J. 2008 Feb 15;121(1269):11-23. http://www.nzma.org.nz/journal/121-1269/2931/
2. Blakely T, Tobias M, Atkinson J. Inequalities in mortality during and after restructuring of the New Zealand economy: Repeated cohort studies. BMJ. 2008 Feb 16;336(7640):371-5. Epub 2008 Jan 24. http://www.bmj.com/cgi/content/full/336/7640/371
3. Blakely T, Ajwani S, Robson B, et al. Decades of disparity: Widening ethnic mortality gaps from 1980 to 1999. N Z Med J. 2004 Aug 6;117(1199). http://www.nzma.org.nz/journal/117-1199/995/
4. Robson B, Harris R. (eds). 2007. Hauora: Māori Standards of Health IV. A study of the years 2000-2005. Wellington: Te Rōpū Rangahau Hauora a Eru Pōmare. Chapter 4 Mortality (Robson B, Purdie G) http://www.hauora.maori.nz/downloads/ hauora_chapter04_web.pdf
5. Ministry of Health and University of Otago. Decades of Disparity III: Ethnic and socioeconomic inequalities in mortality, New Zealand 1981-1999. Wellington. Ministry of Health; 2006. http://www.moh.govt.nz/moh.nsf/pagesmh/4702/$File/ decades-of-disparity-III-pdf
6. Ministry of Health and Ministry of Pacific Island Affairs. 2004 Tupu Ola Moui: Pacific Health Chart Book Wellington: Ministry of Health; 2004. http://www.moh.govt.nz/moh.nsf/0/5C7A9EE42F979B89CC256F0A00149B14/ $File/pacifichcalthchartbook.pdf
7. Ellis CJ, Hamer AW. Cardiovascular health in New Zealand: Areas of concern and targets for improvement in 2008 and beyond. N Z Med J. 2008 Feb 15;121(1269):5-10. http://www.nzma.org.nz/journal/121-1269/ 2927/
8. Metcalfe S, Moodie P. PHARMAC and statins - correction is needed. N Z Med J. 2007 Mar 2;120(1250). http://www.nzma.org.nz/journal/120-1250/ 2453/
9. Moodie P, Dougherty S, Metcalfe S. PHARMAC and statins - getting the best population health gains. N Z Med J. 2006 Jul 21;119(1238). http://www.nzma.org.nz/journal/119-1238/2092/
10. Moodie P, Metcalfe S, McNee W. Response from PHARMAC: Difficult choices. N Z Med J. 2003 Mar 14;116(1170). http://www.nzma.org.nz/journal/ 116-1170/361/
11. Metcalfe S, Moodie P. More about cardiovascular disease and lipid management in New Zealand. N Z Med J. 2002 Oct 11; 115(1163). http://www.nzma.org.nz/journal/115-1163/203/
12. Claxton K, Briggs A, Buxton MJ, et al. Value based pricing for NHS drugs: An opportunity not to be missed? BMJ. 2008 Feb 2;336(7638):251-4. http://www.bmj.com/cgi/content/full/336/7638/251
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet. 1994;344:1383-9.